Sorrento Therapeutics is focused on developing innovative therapies leveraging its proprietary technologies in the fields of immunotherapy and antibody-drug conjugates. The company has made significant advancements in the development of its G-MAB™ library, which is a comprehensive collection of fully human monoclonal antibodies. This library enables Sorrento to identify and produce antibodies that can target a wide range of diseases, including cancer and autoimmune disorders. Additionally, Sorrento is advancing its proprietary ZTlido™ technology, a topical formulation designed for pain relief, which utilizes a unique delivery system to enhance the efficacy of lidocaine.

Furthermore, Sorrento Therapeutics is actively engaged in the development of its next-generation CAR-T cell therapies, which are engineered to enhance the immune system's ability to recognize and attack cancer cells. The company is also exploring the potential of its proprietary Sorrento's COVID-19 antibody therapies, which aim to provide effective treatment options against the virus. Through these technologies, Sorrento Therapeutics is committed to addressing unmet medical needs and improving patient outcomes across various therapeutic areas.

United States

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Cancer

Infectious Diseases

Lung Diseases

Nervous System Diseases

Pathological Conditions

Urogenital Diseases

Sorrento Therapeutics 

Sciatica

Spine disorder

SP-102 is a non-opioid corticosteroid formulated as a viscous gel injection, designed to prolong its analgesic effect at the site of the epidural injection, as demonstrated in clinical and preclinical studies.&nbsp;

SP-102 (SEMDEXA™)

Lung cancer

Lung disease

Non-small cell lung carcinoma

Abivertinib maleate (STI-5656) is a potent, small molecule third-generation tyrosine kinase inhibitor (TKI) of mutant epidermal growth factor receptor (EGFR) and Bruton tyrosine kinase (BTK) receptor
Abivertinib inhibits the gatekeeper mutation of EGFR; T790M, as well as the common activating mutations (L858R, 19del), and has minimal inhibitory activity against the wild type (WT) receptor, contributing to its observed safety profile

STI-5656 (Abivertinib Maleate) (BTK and EGFR inhibitor)

COVID-19

OVYDSO (STI-1558)

Infectious disease

Intranasal COVIDDROPS (STI-2099) may be able to be administered as simple intranasal drops (Figure 1C), which would avoid the need for IV infusion or injection and a hospital visit for treatment.
 
COVI-DROPS is administered as an intranasal instillation in each nares to recently infected patients and utilizes the same neutralizing antibody drug substance as COVI-AMG, the intravenous formulation. The antibody is active against the original SARS-CoV-2 virus as well as the most prevalent viral variants of concern (VoCs) currently infecting the UK and the US. These variants include the UK/Alpha and the India/Delta variants of concern.

COVI-DROPS

Allogeneic culture-expanded adipose-derived Mesenchymal stem cells is a possible therapeutic for the rescue of patients with lung damage and acute respiratory distress syndrome (ARDS) due to COVID-19

COVI-MSC (STI-8282) (CoronaStem1)

Chronic lower back pain

Scilex’s triple-strength SP-103 is an investigational, non-aqueous &nbsp;lidocaine topical system undergoing clinical development in acute LBP &nbsp;conditions. SP-103 builds on the learnings from ZTlido because both &nbsp;products share the same adhesive drug delivery formulation and &nbsp;manufacturing technology. If approved, we believe that SP-103 could &nbsp;become the first-in-class lidocaine topical product for acute LBP &nbsp;indications. All current uses of topical lidocaine products for acute &nbsp;LBP are off label. SP-103 has three times the drug load of ZTlido (108 &nbsp;mg versus 36 mg) in the same adhesive system to potentially deliver &nbsp;threefold the level of the drug within a targeted area, still with the &nbsp;convenience of a single topical system. Additionally, SP-103 is designed &nbsp;to deliver a localized dose of lidocaine that is three times greater &nbsp;than any lidocaine topical product that we are aware of either on the &nbsp;market or in development.

SP-103

STI-1499 (COVI-GUARD™), a COVID-19 targeting monoclonal antibody used as a possible COVID therapy.&nbsp;

STI-1499 (COVIGUARD™)

Castration-resistant prostate cancer

Prostate cancer

Solid tumor/s

Abivertinib maleate (STI-5656) is a potent, small molecule third-generation tyrosine kinase inhibitor (TKI) of mutant epidermal growth factor receptor (EGFR) and Bruton tyrosine kinase (BTK) receptor

Abivertinib Maleate (Fujovee) (STI-5656) (BTK inhibitor) 

Abivertinib Maleate (STI-5656) (BTK inhibitor)

Urothelial cancer

STI-3031 (anti-Pd-L1 antibody)

Stem cells have been demonstrated to support resolution of symptoms in &nbsp;multiple disease settings and have the potential to reduce the long-term &nbsp;effects associated with pulmonary tissue damage for these patients.&nbsp;MSC &nbsp;represent a treatment modality with high potential to help in the fight &nbsp;against COVID-19 as a stand-alone therapy or in synergy with other &nbsp;product candidates in Sorrento’s pipeline, including small molecules &nbsp;(abivertinib or salicyn-30) and neutralizing antibodies (STI-1499 or STI &nbsp;2020).
Source

Sorrento Therapeutics

Company Details